Navigation Links
ThromboGenics Announces 2007 Full Year Results
Date:3/13/2008

LEUVEN, Belgium, March 13 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, today announces a business update and its financial results for the twelve month period ending 31 December 2007. During this period, ThromboGenics has raised additional funds to invest in its development pipeline and has continued to make good progress with its clinical programs.

Highlights

- Successful placing of a total of 5,166,517 shares in May 2007, which increased the Company's free float to 70%, and led to an improvement in stock liquidity. As part of this placement, ThromboGenics issued 2,214,030 new shares raising a total of EUR23.9m. These new funds have strengthened ThromboGenics financial position, and have allowed it to continue to advance its product pipeline and strengthen its operations. The Company's cash position amounted to EUR46.1m as of 31 December 2007.

- Achievement of key milestones with microplasmin for ophthalmic indications. Initiation of a Phase IIb clinical trial of microplasmin in vitrectomy (MIVI III - Microplasmin for Vitreous Injection) in the United States, as well as the initiation of two Phase IIa clinical trials of microplasmin in Europe, for vitreomacular traction and diabetic macular edema (MIVI IIT and MIVI II, respectively). Positive results from the Phase I MIVI I and the MIVI IIT were presented at two international ophthalmology conferences.

- Positive Phase I results with TB-402 (anti-factor VIII), in collaboration with BioInvent International. TB-402 is being developed as a long acting anti-coagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation. The product will enter Phase II clinical studies by the end of 2008.

- Exciting pre-clinical results with TB-403 (anti-PIGF) were published in Cell as the featured article in the November 2, 2007 issue. The paper highlighted that antibodies against PIG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
2. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
3. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
8. EntreMed Announces 2008 Corporate and Clinical Program Priorities
9. Arpida Announces Full Year 2007 Financial Results
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):MSU researcher unveils new approach to treat lower back pain 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10Plate-eating good: Université de Montréal professor designs edible tableware 2Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13924 1Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13924 2VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 1VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 2VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 3VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 4VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 5VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 6VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 7VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 8VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 9New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 1New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 2